Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H3O2.H4N |
Molecular Weight | 77.0825 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[NH4+].CC([O-])=O
InChI
InChIKey=USFZMSVCRYTOJT-UHFFFAOYSA-N
InChI=1S/C2H4O2.H3N/c1-2(3)4;/h1H3,(H,3,4);1H3
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H3N |
Molecular Weight | 17.0305 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08eCurator's Comment: description was created based on several sources, including
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08e
Curator's Comment: description was created based on several sources, including
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14668053https://www.ncbi.nlm.nih.gov/pubmed/2117062
Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: cyanide ions |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CYANOKIT Approved UseCyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3) Launch Date2006 |
|||
Curative | VOSOL Approved UseFor the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. Launch Date1960 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4511.6 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, intramuscular Dose: 20 mg, 1 times / day Route: intramuscular Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 13 years |
|
20 g single, intravenous Highest studied dose Dose: 20 g Route: intravenous Route: single Dose: 20 g Sources: |
unhealthy, 26.9 years Health Status: unhealthy Age Group: 26.9 years Sex: M Sources: |
|
5 g single, intravenous Overdose |
unhealthy, 3 years |
|
5 g single, intravenous |
unhealthy, 62 years |
|
2000 ug 2 times / day multiple, oral Dose: 2000 ug, 2 times / day Route: oral Route: multiple Dose: 2000 ug, 2 times / day Sources: |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Purification and characterization of the nocardial acetylesterase involved in 2-butanone degradation. | 1974 Dec |
|
The degradation of paracetamol (4-hydroxyacetanilide) and other substituted acetanilides by a Penicillium species. | 1975 |
|
Metabolism of resorcinylic compounds by bacteria. Purification and properties of acetylpyruvate hydrolase from Pseudomonas putida 01. | 1975 May 25 |
|
Modification of drug action by hyperammonemia. | 1984 Apr |
|
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury. | 1984 Oct |
|
Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine. | 1985 |
|
Enzymes of vitamin B6 degradation. Purification and properties of two N-acetylamidohydrolases. | 1985 Feb 25 |
|
Enzymes of vitamin B6 degradation. Purification and properties of 5-pyridoxic-acid oxygenase from Arthrobacter sp. | 1986 Nov 15 |
|
Bacterial organomercurial lyase: overproduction, isolation, and characterization. | 1986 Nov 4 |
|
Cloning and sequencing of the gene which encodes the highly inducible acetamidase of Mycobacterium smegmatis. | 1993 Mar |
|
Carbon-arsenic bond cleavage by a newly isolated gram-negative bacterium, strain ASV2. | 1995 Mar |
|
Characterization of two novel propachlor degradation pathways in two species of soil bacteria. | 1999 Feb |
|
Conversion of 4-hydroxyacetophenone into 4-phenyl acetate by a flavin adenine dinucleotide-containing Baeyer-Villiger-type monooxygenase. | 2000 Dec |
|
Evaluation of copper availability to plants in copper-contaminated vineyard soils. | 2001 |
|
Fully automated on-line determination of olanzapine in serum for routine therapeutic drug monitoring. | 2001 Feb |
|
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression. | 2001 Feb |
|
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. | 2001 Feb |
|
Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang). | 2001 Feb |
|
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. | 2001 Feb |
|
Arginine catabolism by Thermanaerovibrio acidaminovorans. | 2001 Feb 20 |
|
Cation-exchange purification of mutagenized bovine beta-casein expressed in transgenic mouse milk: its putative Asn68-linked glycan is heterogeneous. | 2001 Jan |
|
In vitro mixed ruminal microorganism fermentation of whole cottonseed coated with gelatinized corn starch and urea. | 2001 Jan |
|
Teprenone promotes the healing of acetic acid-induced chronic gastric ulcers in rats by inhibiting neutrophil infiltration and lipid peroxidation in ulcerated gastric tissues. | 2001 Jan |
|
Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers. | 2001 Jan |
|
Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography. | 2001 Jan |
|
Measurement of myocardial blood flow with PET using 1-11C-acetate. | 2001 Jan |
|
Expression of alpha-amylase gene in rat liver: liver-specific amylase has a high affinity to glycogen. | 2001 Jan |
|
Acetylcholinesterase assay for rapid expression screening in liquid and solid media. | 2001 Jan |
|
Immunobiology of the reproductive tract in a female baboon. | 2001 Jan |
|
Insecticidal activity of common reagents for insect foreign bodies of the ear. | 2001 Jan |
|
Preparations, characterizations, and structures of (biimidazole)dihalobis(triphenylphosphine)rhenium(III) salts: strong ion-pairing and acid-base properties. | 2001 Jan 1 |
|
Control of electrochemical reactions at the capillary electrophoresis outlet/electrospray emitter electrode under CE/ESI-MS through the application of redox buffers. | 2001 Jan 15 |
|
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores. | 2001 Jan 22 |
|
Identification of lactic acid bacteria constituting the predominating microflora in an acid-fermented condiment (tempoyak) popular in Malaysia. | 2001 Jan 22 |
|
Di-tert-butyl phosphate complexes of cobalt(II) and zinc(II) as precursors for ceramic M(PO3)2 and M2P2O7 materials: synthesis, spectral characterization, structural studies, and role of auxiliary ligands. | 2001 Jan 29 |
|
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. | 2001 Jan 5 |
|
Optimised determination of clobazam in human plasma with extraction and high-performance liquid chromatography analysis. | 2001 Jan 5 |
|
[Acetyl starch as volume substitute, a possible alternative to HES]. | 2001 Jan 5 |
|
Evaluation of a novel vitamin E coated cellulosic membrane hollow fiber dialyzer. | 2001 Jan-Feb |
|
Acute and chronic toxicity of Potassium Chloride (KCl) and Potassium Acetate (KC(2)H(3)O(2)) to Daphnia similis and Ceriodaphnia dubia (Crustacea; Cladocera). | 2001 Mar |
|
Measurement of low picomolar levels of triamcinolone acetonide in human bronchoalveolar lavage fluid by gas chromatography-electron-capture negative-ion mass spectrometry. | 2001 Mar 1 |
|
Ammonia-induced heme oxygenase-1 expression in cultured rat astrocytes and rat brain in vivo. | 2002 Dec |
|
Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. | 2003 Aug 15 |
|
Cobalamin transport proteins and their cell-surface receptors. | 2003 Jun 13 |
|
Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. | 2004 Jun |
|
[Antioxidant enzymes of the rat liver, brain, heart and erythrocytes in ammonia intoxication]. | 2005 Mar-Apr |
|
Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain. | 2005 Oct |
|
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis. | 2010 Jan 22 |
|
Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. | 2010 Mar |
|
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex. | 2010 Sep |
Patents
Sample Use Guides
Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6692038
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:40 GMT 2025
by
admin
on
Mon Mar 31 17:51:40 GMT 2025
|
Record UNII |
RRE756S6Q2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
631-61-8
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
211-162-9
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
62947
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
100000088037
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
1362883
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID5023873
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
RRE756S6Q2
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
RRE756S6Q2
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
C45678
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
CONCEPT | Industrial Aid | ||
|
C77452
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
12432
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
SUB12869MIG
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
556
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
C018824
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | |||
|
m1762
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY | Merck Index | ||
|
AMMONIUM ACETATE
Created by
admin on Mon Mar 31 17:51:40 GMT 2025 , Edited by admin on Mon Mar 31 17:51:40 GMT 2025
|
PRIMARY |